Organon & Co. (OGN) Analyse boursière

Présentation de l'entreprise

Organon & Co. (OGN) operates within the healthcare sector, specifically functioning as a drug manufacturer focused on the general pharmaceutical industry. The enterprise develops and delivers specialized women's health solutions through a comprehensive portfolio of prescription therapies and medical devices. This operational scope extends across major international markets, including the United States, Europe, Canada, Japan, China, Latin America, the Middle East, and various other regions globally. The company maintains a significant operational scale, employing approximately 10,000 individuals worldwide to support its distribution and development activities. With a market capitalization of 1.52 billion dollars and annual revenue reaching 6.22 billion dollars over the trailing twelve months, Organon represents a mid-to-large cap entity in the pharmaceutical landscape. These financial dimensions indicate a substantial asset base and revenue generation capability, positioning the firm as a established player capable of sustaining extensive R&D and commercialization efforts in the women's health domain.

Santé financière

The company reported revenue of 6.22 billion dollars for the trailing twelve months, with net income standing at 187 million dollars and EBITDA reaching 1.65 billion dollars. The disparity between the gross revenue figure and the net income results highlights a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line growth to arrive at final profitability. Free cash flow generation was measured at 190.12 million dollars, providing a measure of financial flexibility that allows the organization to fund operations, service debt, or pursue strategic initiatives without relying solely on external financing. The firm's profitability is characterized by a gross margin of 54.3%, an operating margin of 16.2%, and a profit margin of 3.0%, reflecting the high fixed cost nature of pharmaceutical manufacturing where operational leverage is critical. On the liability side, total cash holdings of 574 million dollars are offset by a total debt burden of 8.80 billion dollars, resulting in a debt-to-equity ratio of 1170.21, which indicates a highly leveraged balance sheet typical of capital-intensive biopharmaceutical firms. Despite the high leverage, the current ratio of 1.82 suggests adequate short-term liquidity to cover immediate obligations. Return on equity stands at 30.6% while return on assets is 6.2%, metrics that reveal the efficiency with which management utilizes shareholder equity and total assets to generate earnings, with the high ROE partly attributable to the substantial financial leverage employed by the company.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is 8.11, while the forward P/E is significantly lower at 1.57, implying that the market expects earnings to expand substantially in the future or that current earnings are depressed due to temporary factors. The price-to-book ratio of 2.02 indicates that the stock trades at a moderate premium over its book value, suggesting investors are willing to pay slightly more than the net asset value for the firm's equity. Alternative valuation metrics, including a price-to-sales ratio of 0.24 and an EV/EBITDA of 5.89, suggest the stock is priced relatively conservatively compared to its revenue generation and earnings power before interest and taxes. The 52-week price range fluctuates between a low of 5.83 dollars and a high of 15.85 dollars, providing a historical context for current trading levels relative to recent volatility. The beta of 0.57 indicates that the stock exhibits lower price volatility than the broader market, moving less aggressively in response to general market swings.

Growth & Income

Revenue growth for the trailing twelve months was -5.3%, while earnings growth data is not available in the current reporting period, meaning revenue contraction is the primary driver of recent performance dynamics. In the absence of specific earnings growth figures to compare against revenue decline, the negative revenue growth rate suggests a contraction in the top line that directly impacts profitability unless offset by significant cost reductions. The company distributes a dividend with a yield of 1.4% and maintains a payout ratio of 47.2%, indicating that the dividend coverage is reasonable relative to the reported net income of 187 million dollars. The payout ratio suggests a conservative approach to dividend distribution that allows the firm to retain a significant portion of earnings for debt servicing given the high debt load. The overall profile combines a period of revenue contraction with a conservative dividend policy, presenting a scenario where income generation is prioritized despite recent top-line weakness.